LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. By decoding the language of the neuroimmune cross-talk, we are developing first-in-class therapeutic products – NRILs: neuronal reprogrammers of innate lymphocytes – to preserve health and treat inflammatory, infectious and metabolic diseases. We are bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients. 

Akcea Therapeutics is a development and commercialization company focused on helping patients living with serious and rare diseases.

Our priority is to bring transformative medicines to patients by driving clinical program execution, understanding patient and physician needs, preparing the market, creating market access, and commercializing our products on a global basis.

Akcea, an affiliate of Ionis Pharmaceuticals, was established in early 2015 and based in Kendall Square in Cambridge, Massachusetts. Akcea has a robust portfolio of development- and registration-stage drugs covering multiple targets and diseases using advanced RNA-targeted antisense therapeutics. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Ionis standards of excellence.

Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam was founded in 2002 on a bold vision to turn scientific possibility into reality, which is now marked by its robust discovery platform and deep pipeline of investigational medicines, including 5 programs in late-stage clinical development.

Alnylam Home

original products based on recombinant DNA technology and molecular biology

Amgen, a world leader in biotechnology, has been exploring the power of scientific innovation to decisively improve patient’s lives for 30 years.
Amgen is on the cutting edge of developing original products based on recombinant DNA technology and molecular biology, having launched the first revolutionary biotechnology drugs. Today, Amgen is on the Fortune 500 list, helps millions of patients in the fight against serious diseases and continues to be true to its principles based on science.
First Portuguese Science and Technology Park specialized on Biotechnology

BIOCANT is a CLUSTER of companies and R&D institutions of excellence with a strong commitment to science education and entrepreneurship.
A unique ecosystem that covers the entire INNOVATION PIPELINE, from the knowledge generation and human resources training to the market, including tech transfer, financing, scientific dissemination and industrial production.
It gathers 30% of the total national number of BIOTECH COMPANIES and provides a wide variety of services and opportunities to develop a competitive business.

Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.


Biotrend is a research-based company focused on the development, optimization, de-risking, integration and scale-up of bioprocesses for the production of bio-based chemicals, materials and fuels from renewable raw materials, including complex industrial by-products and wastes. We offer contract research and development services and develop new technologies to be licensed out to industrial clients. We actively participate in international collaborative projects encompassing the full bioeconomy value chain, keeping Biotrend at the forefront of scientific development.

BSIM Therapeutics is a biotech company focused on the design of organ-targeted, high-quality drug candidates for the treatment of transthyretin-mediated amyloidoses. We work closely with patients and physicians to understand and answer to multiple clinical manifestations representing unmet medical needs.

The mission of Coimbra Genomics is to bring individualized medicine to the work environment of every physician. It has therefore developed ELSIE, a genome-based decision-making platform that allows the connection between genome knowledge and clinical practice, helping facilitate the making of important clinical decisions, adapted to the genetic characteristics of each user during normal visits to the doctor. ELSIE is being used on a pilot basis in several countries and began to be used clinically in Germany in 2016.

GenIbet is a biopharmaceutical CMO offering highly specialized Microbial, Cell Culture and Viral Process Development and cGMP manufacturing services to research groups, biotech and pharma companies. This, combined with in-house fill and finish capabilities, gives our clients the opportunity to go from bench to clinic in one facility.
GenIbet’s core activity is the manufacture and supply of materials for use in early stage drug development, pre-clinical studies and cGMP manufacturing from Phase I to Phase III clinical trials.

HeartGenetics is dedicated to keeping people healthy through the use of genetic information.

We help our clients define diet and exercise plans that improve health.

Based on more than 15 years of research in cardiovascular and bioinformatics, HeartGenetics’ R&D team developed new wellness genetic tests and reports that are instrumental in the definition of highly personalised lifestyle plans.

Founded in 2013, the company main goal is to play a key role in applied genetic knowledge and genetic testing, going into the wellness space.


As part of the Calouste Gulbenkian Foundation, the Instituto Gulbenkian Ciência (IGC) is an institute dedicated to biological and biomedical research and innovative postgraduate training, placing science at the heart of society.

400 scientists, from 41 different nationalities, aim to understand the fundamental principles of Biology, in particular how the organism is formed and interacts with its environment, leading to novel approaches towards disease treatment and world sustainability.



Bacterial sepsis is responsible for the death of 1.35 million Babies, stillbirths and 1-month old, every year. In addition, preterm birth and morbidity caused by bacterial infections represent an annual cost of nearly US$ 12B a year in the US alone. This is currently an unmet medical need as there is no treatment (pre-infection) able to prevent bacterial infections in fetus and newborns and thus prevent stillbirths and preterm births. Our neonatal vaccine, administered to women, induces the production of protective antibodies in the mother that will be transferred to the fetus protecting the fetus and newborn from bacterial infections. Pre-clinical trials in a mice model of infection showed over 80% survival rate in neonates from immunized mothers, contrasting with the absence of those from non-immunized mothers.
We bring innovative products, services and solutions to people throughout the world.

We’re more than 30,000 people working hard to prevent, treat, cure and stop some of the most devastating and complex diseases of our time. From heart disease to HIV, Alzheimer’s disease to cancer, we are committed to issues that touch everyone’s lives.

Luzitin is a privately owned pharmaceutical company, focused on the development of photosensitizer compounds for Photodynamic Therapy (PDT).
Founded in 2010, after five years of research collaboration between Bluepharma, the University of Coimbra and the Hospitals of the University of Coimbra, Luzitin is developing a novel and very promising therapeutic procedure for solid tumors (LUZ11) and Acne (LUZACNE). Its proprietary technology consists of a combination of new generation photosensitizer with a specific infrared-laser medical device.
Woldwide solutions for molecular testing at point of care

NANO4 Global aims to provide solutions for one step molecular identification of DNA/RNA at point-of-care (PoC). NANO4 Global spins around an awarded platform — NANO4 – the next generation of molecular nanodiagnostics applied to lifesciences.

Ophiomics was born from a collaboration between scientists with clinicians sharing the purpose of bringing the latest advances in genomics, bioinformatics and clinical research in support of a Precision Oncology. Ophiomics develops and offers advanced genetic and genomic tests in support of diagnostic, prognostic, pharmacogenomics and clinical follow up. We process both FFPE and Liquid Biospies (based on circulating cell free DNA) to characterise mutational landscapes of tumours, providing guidance for therapy and non-invasive assessments of response to treatment. We offer clinical testing to cancer centres alongside a strong emphasis in clinically-oriented research.

A biopharmaceutical company focused on the discovery and development of new pharmaceutical drugs based on novel marine compounds for unmet clinical needs.


Computational Biology Solutions for the Life Sciences

SilicoLife develops state-of-the-art optimization algorithms and uses proprietary computational and modelling tools to accelerate the design of microbial strains, based on metabolic engineering and synthetic biology approaches, shortening the development time and costs of new highly effective processes for the production of specific target compounds such as biofuels, chemicals, food ingredients or biopolymers.

Stemmatters is an ambitious regenerative medicine company developing game changing medical devices and combination products for large unmet medical needs.
Research and development centres on unique medical device development platforms, which offer excellent scope for tailoring biological and physicochemical performance for breakthrough applications in regenerative medicine. Fully integrated with specialized and resourceful competences in research and development, Stemmatters additionally offers unique manufacturing competences in regenerative medicine products for external entities.

TREAT U is developing more effective and safer products for cancer patients by increasing therapeutic efficacy and reducing adverse side effects, hence reducing treatment costs for healthcare systems.
Our first product – PEGASEMP™ – is a proprietary nanotechnology-based delivery platform with application in diagnostics and therapy. PEGASEMP™ targets specifically the tumor microenvironment with triggered delivery of the payload, creating new opportunities in personalized medicine and new value to the Pharmaceutical Market.